Last reviewed · How we verify
Osteocel Plus — Competitive Intelligence Brief
phase 2
Biologic
Live · refreshed every 30 min
Target snapshot
Osteocel Plus (Osteocel Plus) — NuVasive.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Osteocel Plus TARGET | Osteocel Plus | NuVasive | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Osteocel Plus CI watch — RSS
- Osteocel Plus CI watch — Atom
- Osteocel Plus CI watch — JSON
- Osteocel Plus alone — RSS
Cite this brief
Drug Landscape (2026). Osteocel Plus — Competitive Intelligence Brief. https://druglandscape.com/ci/osteocel-plus. Accessed 2026-05-13.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab